Cannabis use in endometriosis: systematic scoping review

Introduction and clinical context

The study Cannabis use in endometriosis: systematic scoping review (PMC · 2025) is part of the scientific research on the use of cannabinoids in endometriosis and pelvic pain.

Endometriosis, characterized by chronic pelvic pain and a major impact on quality of life, is a growing area of medical-cannabis research. Observational studies and reviews indicate that pain is the main reason reported for cannabis use by these patients, with reports of symptomatic relief. The evidence is still mostly observational — controlled clinical trials are lacking — and use should be guided by a healthcare professional.

Understanding what science shows about the use of cannabinoids in endometriosis and pelvic pain helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This scientific review gathered and critically appraised the available literature on the topic. Review of 9 studies (1,787 participants): pain was the most common indication for cannabis use. As a synthesis of multiple studies, it offers a more robust picture than isolated reports, though it depends on the quality of the included works. For clinical practice, syntheses like this help calibrate expectations and support clinical decisions.

Mechanism of action and safety

The endocannabinoid system is present in the uterus and pelvic tissues, taking part in the modulation of pain and inflammation — the basis for studying cannabinoids in endometriosis pain; the reported relief would involve the reduction of central pain and local inflammation. Regarding safety, effects such as drowsiness and dizziness predominate, with attention to interactions and to use in reproductive age (use is advised against in pregnancy). As the evidence is mostly observational, use should be individualized and guided by a healthcare professional.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PMC · 2025). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis help with endometriosis pain?

Observational studies report pain relief; controlled trials are lacking, and use should be guided by a doctor.

What is the main reason for use in endometriosis?

Pain is the most common indication reported in the research.